Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
Manfredi Rizzo,Alessandro Colletti,Peter E Penson,Niki Katsiki,Dimitri P Mikhailidis,Peter P Toth,Ioanna Gouni-Berthold,John Mancini,David Marais,Patrick Moriarty,Massimiliano Ruscica,Amirhossein Sahebkar,Dragos Vinereanu,Arrigo Francesco Giuseppe Cicero,Maciej Banach,International Lipid Expert Panel (ILEP),Julio Acosta,Mutaz Al-Khnifsawi,Fahad Alnouri,Fahma Amar,Atanas G Atanasov,Gani Bajraktari,Sonu Bhaskar,Agata Bielecka-Dąbrowa,Bojko Bjelakovic,Eric Bruckert,Ibadete Bytyçi,Alberto Cafferata,Richard Ceska,Arrigo F G Cicero,Krzysztof Chlebus,Xavier Collet,Magdalena Daccord,Olivier Descamps,Dragan Djuric,Ronen Durst,Marat V Ezhov,Zlatko Fras,Dan Gaita,Adrian V Hernandez,Steven R Jones,Jacek Jozwiak,Nona Kakauridze,Amani Kallel,Amit Khera,Karam Kostner,Raimondas Kubilius,Gustavs Latkovskis,G B John Mancini,A David Marais,Seth S Martin,Julio Acosta Martinez,Mohsen Mazidi,Erkin Mirrakhimov,Andre R Miserez,Olena Mitchenko,Natalya P Mitkovskaya,Patrick M Moriarty,Seyed Mohammad Nabavi,Devaki Nair,Demosthenes B Panagiotakos,György Paragh,Daniel Pella,Zaneta Petrulioniene,Matteo Pirro,Arman Postadzhiyan,Raman Puri,Ashraf Reda,Željko Reiner,Dina Radenkovic,Michał Rakowski,Jemaa Riadh,Dimitri Richter,Maria-Corina Serban,Abdullah M A Shehab,Aleksandr B Shek,Cesare R Sirtori,Claudia Stefanutti,Tomasz Tomasik,Margus Viigimaa,Pedro Valdivielso,Branislav Vohnout,Stephan von Haehling,Michal Vrablik,Nathan D Wong,Hung-I Yeh,Jiang Zhisheng,Andreas Zirlik
DOI: https://doi.org/10.1016/j.phrs.2023.106679
Abstract:Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10-25% of the general adult population, 15% of children, and even > 50% of individuals who have type 2 diabetes mellitus. It is a major cause of liver-related morbidity, and cardiovascular (CV) mortality is a common cause of death. In addition to being the initial step of irreversible alterations of the liver parenchyma causing cirrhosis, about 1/6 of those who develop NASH are at risk also developing CV disease (CVD). More recently the acronym MAFLD (Metabolic Associated Fatty Liver Disease) has been preferred by many European and US specialists, providing a clearer message on the metabolic etiology of the disease. The suggestions for the management of NAFLD are like those recommended by guidelines for CVD prevention. In this context, the general approach is to prescribe physical activity and dietary changes the effect weight loss. Lifestyle change in the NAFLD patient has been supplemented in some by the use of nutraceuticals, but the evidence based for these remains uncertain. The aim of this Position Paper was to summarize the clinical evidence relating to the effect of nutraceuticals on NAFLD-related parameters. Our reading of the data is that whilst many nutraceuticals have been studied in relation to NAFLD, none have sufficient evidence to recommend their routine use; robust trials are required to appropriately address efficacy and safety.